A review of the animal pharmacology of ranitidine--a new, selective histamine H2-antagonist.
The animal pharmacology and metabolism of ranitidine have been reviewed. Experiments using guinea-pig isolated right atrium and ileum preparations have shown that ranitidine is a selective, potent, and competitive histamine H2-receptor antagonist. In the conscious dog gastric acid secretion induced by histamine, pentagastrin, bethanechol and food was inhibited by ranitidine at doses 4 to 12 times lower than equi-effective doses of cimetidine. Ranitidine inhibited the formation of aspirin-induced gastric lesions, both in the presence and absence of gastric acid. Unlike cimetidine, ranitidine neither possessed anti-androgenic activity, nor did it inhibit the mixed function oxygenase metabolizing enzyme system in the liver. Ranitidine has been recommended for clinical trial in the treatment of peptic ulcer disease.
D000284:Administration, Oral; D000818:Animals; D001241:Aspirin; D001626:Bethanechol Compounds / Q000494:pharmacology; D002927:Cimetidine / Q000494:pharmacology; D004285:Dogs; D005663:Furans / Q000008:administration & dosage / Q000494:pharmacology*; D005744:Gastric Acid / Q000378:metabolism; D005753:Gastric Mucosa / Q000187:drug effects; D006168:Guinea Pigs; D006325:Heart Atria / Q000187:drug effects; D006632:Histamine / Q000494:pharmacology; D006635:Histamine H2 Antagonists / Q000008:administration & dosage / Q000494:pharmacology*; D066298:In Vitro Techniques; D007275:Injections, Intravenous; D008297:Male; D009200:Myocardial Contraction / Q000187:drug effects; D011467:Prostate / Q000187:drug effects; D011899:Ranitidine; D051381:Rats; D013276:Stomach Ulcer / Q000517:prevention & control
D001626:Bethanechol Compounds; D005663:Furans; D006635:Histamine H2 Antagonists; D002927:Cimetidine; D006632:Histamine; D011899:Ranitidine; D001241:Aspirin